Spridningsemission ska locka fler svenska ägare till BBS – Bioactive Bone Substitutes #SweLifeScience #BioStockSwe.

Teckningsperiod 2 juni 2020 - 16 juni 2020. BBS-Bioactive Bone Substitutes Oyj, är ett finskt medicinteknikbolag som har utvecklat ett innovativt

16:54. Pääkirjoitus ja liputusten jälkipuinti Päivitetty 4 t sitten BBS - Bioactive Bone Substitutes Päivitetty 4 t sitten Everfuel - vetyasemia Eurooppaan Päivitetty 5 t t sitten Peptonic Medical AB - naisten elämää parantavan mission alkumetreillä Päivitetty 5 t sitten BBS - Bioactive Bone Substitutes Päivitetty Bayn Europe, BBC, BBS, BBS-Bioactive Bone Substitutes, BE Group, Bedrägeri Euronext, Europa, Europabörserna, Europaterminer, European Bavarian Nordic, Bayn Europe, BBS-Bioactive Bone Substitutes, BE Group Bonava B, BONESUPPORT, Bong, Bonäsudden Holding, Boozt, Borr Drilling BBS-Bioactive Bone Substitutes, BE Group, Bedrägeri, Bedrägerier, Befolkningsutveckling, Beige Book, Beijer Alma, Beijer Electronics. BBS-Bioactive Bone Substitutes Oyj. Phone +358 (0) 40 7080 307 E-mail info@bbs-artebone.fi Www www.bbs-artebone.fi. OULU HEADQUARTERS.

Stock Exchange Release April 7th, 2021 at 6.00 pm. INVITATION TO THE BBS-BIOACTIVE BONE SUBSTITUTES PLC’S ANNUAL GENERAL MEETING (AGM) The shareholders of BBS-Bioactive Bone Substitutes Plc are invited to the company’s Annual General Meeting, which is held at the company’s premises at Kiviharjunlenkki 6, 90220 Oulu, on Wednesday April 28th 2021 starting at 2.00 pm. BBS-Bioactive Bone Substitutes is the 8 th company to be admitted to trading on Nasdaq’s Nordic markets* in 2018, and it represents the 2nd listing on Nasdaq Helsinki in 2018. BBS-Bioactive Bone Substitutes Plc (”BBS”) is a Finnish health technology company that has developed a new generation innovative medical device product for the treatment of bone defects in orthopaedic and BBS-Bioactive Bone Substitutes Plc: New Schedule Estimate for the CE Marking of Company’s ARTEBONE® Product 23.12.2020, 13:00 · GlobeNewswire BBS-Bioactive Bone Substitutes Plc: Correction to the release of BBS-Bioactive Bone Substitutes Plc published on 21.12.2020 at 16:30 CET BBS-BIOACTIVE BONE SUBSTITUTES OYJ Merkintäoikeusanti Enintään 1 301 205 osaketta Merkintähinta 4,20 euroa tai 44,42 Ruotsin kruunua osakkeelta Suomessa rekisteröity julkinen osakeyhtiö BBS-Bioactive Bone Substitutes Oyj ("Yhtiö" tai “BBS”) tarjoaa osakkeenomistajien merkintäetuoikeuteen 1 Feb 2021 BBS-Bioactive Bone Substitutes (BBS) is a biomedical technology company developing innovative, biologically active medical device implants BBS-Bioactive Bone Substitutes Oyj is a health technology company.

BBS-Bioactive Bone Substitutes (BBS) is a biomedical technology company developing innovative, biologically active medical device implants För en (1) aktie i BBS-Bioactive Bone Substitutes får du en (1) teckningsrätt. Fyra (4) teckningsrätter ger dig möjlighet att teckna, d v s köpa, BONES.

BBS-Bioactive Bone Substitutes Oyj (BBS) är ett Finland-baserat bolag som är verksamt inom medicinsk utrustning industrin. Bolaget fungerar som ett bioteknikbolag som utvecklar och distribuerar implantat för medicinskt bruk som används vid ortopedisk kirurgi.

BBS-Bioactive Bone Substitutes komplett bolagsfakta från DI.se. Affärsvärldens IPO-guide granskar Bioactive Bone Substitutes notering.

Stock Exchange Release April 7th, 2021 at 6.00 pm. INVITATION TO THE BBS-BIOACTIVE BONE SUBSTITUTES PLC’S ANNUAL GENERAL MEETING (AGM) The shareholders of BBS-Bioactive Bone Substitutes Plc are invited to the company’s Annual General Meeting, which is held at the company’s premises at Kiviharjunlenkki 6, 90220 Oulu, on Wednesday April 28th 2021 starting at 2.00 pm.

Healthcare Technology. OUR SOLUTION Our fisrt product, ARTEBONE, is paste in a BBS-Bioactive Bone Substitutes är verksamma inom medicinteknik. Bolaget designar, utvecklar och konstruerar biologiska implantat för patienter med benfel 31 Jan 2018 BBS-Bioactive Bone Substitutes said today that's its planning for an initial public offering later this year it hopes will bring in some $10 million. 20 Feb 2020 The clinical investigation run by BBS-Bioactive Bone Substitutes Oyj in clinical centers in Finland and Poland has been finalized and reported. In Katso osakkeen BBS-BIOACTIVE BONE SUBSTITUTES OYJ NPV tiedot, graafi, tuotto, osinko, kurssi ja tarjoustasot.

BBS-Bioactive Bone Substitutes Oyj Teollisuustie 4 … BBS-Bioactive Bone Substitutes Plc: ANNUAL REPORT 2020 has been published.
Avslag sjukpenning utmattningssyndrom

Bolagets patenterade lösning går under varumärket Artebone och baseras på tricalciumfosfat (TCP) och benprotein, som stimulerar och påskyndar benläkningsprocessen.

We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery.
What is functional organizational

tusen dagar i sverige morteza
hitta båtplats stockholm
nacka hotell
älvsjö hemtjänst lediga jobb
karlinflammation symptom

BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiologic biotech company. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery.

OULU HEADQUARTERS. BBS-Bioactive Bone Substitutes Oyj Kiviharjunlenkki 6 90220 Oulu Finland. REISJÄRVI PRODUCTION SITE. BBS-Bioactive Bone Substitutes Oyj Teollisuustie 4 … BBS-Bioactive Bone Substitutes Oyj:n (BBS) ydinosaamiseen kuuluu helppokäyttöisten ja käyttövalmiiden luun muodostusta ja paranemista edistävien luunkorvikeimplanttien kehittäminen ja valmistaminen.

BBS-Bioactive Bone Substitutes Plc: ANNUAL REPORT 2020 has been published. Annual report release on 31 March 2021 at 09.00 a.m. (CET) BBS Oyj’s Annual Report for 2020 has been published 31.3.2021. The Publication is attached to this release and can be found at https://www.bbs-artebone.fi/investors/financial-reports/.

INVITATION TO THE BBS-BIOACTIVE BONE SUBSTITUTES PLC’S ANNUAL GENERAL MEETING (AGM) The shareholders of BBS-Bioactive Bone Substitutes Plc are invited to the company’s Annual General Meeting, which is held at the company’s premises at Kiviharjunlenkki 6, 90220 Oulu, on Wednesday April 28th 2021 starting at 2.00 pm. BBS-Bioactive Bone Substitutes is the 8 th company to be admitted to trading on Nasdaq’s Nordic markets* in 2018, and it represents the 2nd listing on Nasdaq Helsinki in 2018. BBS-Bioactive Bone Substitutes Plc (”BBS”) is a Finnish health technology company that has developed a new generation innovative medical device product for the treatment of bone defects in orthopaedic and BBS-Bioactive Bone Substitutes Plc: New Schedule Estimate for the CE Marking of Company’s ARTEBONE® Product 23.12.2020, 13:00 · GlobeNewswire BBS-Bioactive Bone Substitutes Plc: Correction to the release of BBS-Bioactive Bone Substitutes Plc published on 21.12.2020 at 16:30 CET BBS-BIOACTIVE BONE SUBSTITUTES OYJ Merkintäoikeusanti Enintään 1 301 205 osaketta Merkintähinta 4,20 euroa tai 44,42 Ruotsin kruunua osakkeelta Suomessa rekisteröity julkinen osakeyhtiö BBS-Bioactive Bone Substitutes Oyj ("Yhtiö" tai “BBS”) tarjoaa osakkeenomistajien merkintäetuoikeuteen 1 Feb 2021 BBS-Bioactive Bone Substitutes (BBS) is a biomedical technology company developing innovative, biologically active medical device implants BBS-Bioactive Bone Substitutes Oyj is a health technology company. The firm engages in the development, research, production and manufacture of bioactive Stockopedia rates BBS-Bioactive Bone Substitutes Oyj as a Highly Speculative Sucker Stock . brokers rate it as a 'Strong Buy'. Click to view HEX:BONEH's Stockopedia rates BBS-Bioactive Bone Substitutes Oyj as a Highly Speculative Sucker Stock .

År. Kommentarer. Aktien är noterad på First North. 2018. Ny notering på First North den 28 februari, introduktionskurs 5,50 EUR. Emissioner m.m. BONEH, BBS-Bioactive Bone Substitutes, (FI4000260583) Trading; Overview; Performance; Key Ratios; Financials; Fact Sheet ; Company Fact Sheet FAQ & Methodology BBS-Bioactive Bone Substitutes Oyj (BBS) är ett Finland-baserat bolag som är verksamt inom medicinsk utrustning industrin. Bolaget fungerar som ett bioteknikbolag som utvecklar och distribuerar implantat för medicinskt bruk som används vid ortopedisk kirurgi.